Werewolf Therapeutics, Inc. (HOWL): Free Cash Flow
-$60.29M
Year ended 2025-12-31
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$60.29M | n/m | 2026-03-27, From 2025-01-01 |
| 2024-12-31 | -$56.44M | n/m | 2026-03-27, From 2024-01-01 |
| 2023-12-31 | -$33.38M | n/m | 2025-03-11, From 2023-01-01 |
| 2022-12-31 | -$44.21M | n/m | 2024-03-07, From 2022-01-01 |
| 2021-12-31 | -$43.37M | n/m | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | -$19.18M | n/a | 2022-03-24, From 2020-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Werewolf Therapeutics, Inc. (HOWL) | 2025-12-31 | -$60.29M | n/m |
| Context Therapeutics Inc. (CNTX) | 2025-12-31 | -$26.42M | n/m |
| Corvus Pharmaceuticals, Inc. (CRVS) | 2025-12-31 | -$32.97M | n/a |
| Inovio Pharmaceuticals, Inc. (INO) | 2025-12-31 | -$88.92M | n/m |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $4.83M | n/m |
| Rallybio Corp (RLYB) | 2024-12-31 | -$49.28M | n/m |
| OnKure Therapeutics, Inc. (OKUR) | 2025-12-31 | -$51.87M | n/m |
| Lifevantage Corp (LFVN) | 2026-06-30 | $6.67M | -36.5% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | -$33.54M | n/m |
Compare HOWL, CNTX, CRVS, INO side by side · Screen every company in Pharmaceutical Preparations ↗